Wieke M van Oostveen1, Elizabeth C M de Lange2. 1. Faculty of Science, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands. 2. Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre of Drug Research, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands.
Abstract
BACKGROUND: Alzheimer's disease (AD) is a progressive neurodegenerative disorder affecting many individuals worldwide with no effective treatment to date. AD is characterized by the formation of senile plaques and neurofibrillary tangles, followed by neurodegeneration, which leads to cognitive decline and eventually death. INTRODUCTION: In AD, pathological changes occur many years before disease onset. Since disease-modifying therapies may be the most beneficial in the early stages of AD, biomarkers for the early diagnosis and longitudinal monitoring of disease progression are essential. Multiple imaging techniques with associated biomarkers are used to identify and monitor AD. AIM: In this review, we discuss the contemporary early diagnosis and longitudinal monitoring of AD with imaging techniques regarding their diagnostic utility, benefits and limitations. Additionally, novel techniques, applications and biomarkers for AD research are assessed. FINDINGS: Reduced hippocampal volume is a biomarker for neurodegeneration, but atrophy is not an AD-specific measure. Hypometabolism in temporoparietal regions is seen as a biomarker for AD. However, glucose uptake reflects astrocyte function rather than neuronal function. Amyloid-β (Aβ) is the earliest hallmark of AD and can be measured with positron emission tomography (PET), but Aβ accumulation stagnates as disease progresses. Therefore, Aβ may not be a suitable biomarker for monitoring disease progression. The measurement of tau accumulation with PET radiotracers exhibited promising results in both early diagnosis and longitudinal monitoring, but large-scale validation of these radiotracers is required. The implementation of new processing techniques, applications of other imaging techniques and novel biomarkers can contribute to understanding AD and finding a cure. CONCLUSIONS: Several biomarkers are proposed for the early diagnosis and longitudinal monitoring of AD with imaging techniques, but all these biomarkers have their limitations regarding specificity, reliability and sensitivity. Future perspectives. Future research should focus on expanding the employment of imaging techniques and identifying novel biomarkers that reflect AD pathology in the earliest stages.
BACKGROUND:Alzheimer's disease (AD) is a progressive neurodegenerative disorder affecting many individuals worldwide with no effective treatment to date. AD is characterized by the formation of senile plaques and neurofibrillary tangles, followed by neurodegeneration, which leads to cognitive decline and eventually death. INTRODUCTION: In AD, pathological changes occur many years before disease onset. Since disease-modifying therapies may be the most beneficial in the early stages of AD, biomarkers for the early diagnosis and longitudinal monitoring of disease progression are essential. Multiple imaging techniques with associated biomarkers are used to identify and monitor AD. AIM: In this review, we discuss the contemporary early diagnosis and longitudinal monitoring of AD with imaging techniques regarding their diagnostic utility, benefits and limitations. Additionally, novel techniques, applications and biomarkers for AD research are assessed. FINDINGS: Reduced hippocampal volume is a biomarker for neurodegeneration, but atrophy is not an AD-specific measure. Hypometabolism in temporoparietal regions is seen as a biomarker for AD. However, glucose uptake reflects astrocyte function rather than neuronal function. Amyloid-β (Aβ) is the earliest hallmark of AD and can be measured with positron emission tomography (PET), but Aβ accumulation stagnates as disease progresses. Therefore, Aβ may not be a suitable biomarker for monitoring disease progression. The measurement of tau accumulation with PET radiotracers exhibited promising results in both early diagnosis and longitudinal monitoring, but large-scale validation of these radiotracers is required. The implementation of new processing techniques, applications of other imaging techniques and novel biomarkers can contribute to understanding AD and finding a cure. CONCLUSIONS: Several biomarkers are proposed for the early diagnosis and longitudinal monitoring of AD with imaging techniques, but all these biomarkers have their limitations regarding specificity, reliability and sensitivity. Future perspectives. Future research should focus on expanding the employment of imaging techniques and identifying novel biomarkers that reflect AD pathology in the earliest stages.
Entities:
Keywords:
Alzheimer’s disease; MRI; PET; amyloid-β; early diagnosis; imaging techniques; longitudinal monitoring; tau
Authors: Marta Marquié; Marc D Normandin; Avery C Meltzer; Michael Siao Tick Chong; Nicolas V Andrea; Alejandro Antón-Fernández; William E Klunk; Chester A Mathis; Milos D Ikonomovic; Manik Debnath; Elizabeth A Bien; Charles R Vanderburg; Isabel Costantino; Sara Makaretz; Sarah L DeVos; Derek H Oakley; Stephen N Gomperts; John H Growdon; Kimiko Domoto-Reilly; Diane Lucente; Bradford C Dickerson; Matthew P Frosch; Bradley T Hyman; Keith A Johnson; Teresa Gómez-Isla Journal: Ann Neurol Date: 2017-01 Impact factor: 10.422
Authors: Jasper D Sluimer; Wiesje M van der Flier; Giorgos B Karas; Nick C Fox; Philip Scheltens; Frederik Barkhof; Hugo Vrenken Journal: Radiology Date: 2008-06-23 Impact factor: 11.105
Authors: Christopher C Rowe; Uwe Ackerman; William Browne; Rachel Mulligan; Kerryn L Pike; Graeme O'Keefe; Henry Tochon-Danguy; Gordon Chan; Salvatore U Berlangieri; Gareth Jones; Kerryn L Dickinson-Rowe; Hank P Kung; Wei Zhang; Mei Ping Kung; Daniel Skovronsky; Thomas Dyrks; Gerhard Holl; Sabine Krause; Matthias Friebe; Lutz Lehman; Stefanie Lindemann; Ludger M Dinkelborg; Colin L Masters; Victor L Villemagne Journal: Lancet Neurol Date: 2008-01-10 Impact factor: 44.182
Authors: David M Cash; Jonathan D Rohrer; Natalie S Ryan; Sebastien Ourselin; Nick C Fox Journal: Alzheimers Res Ther Date: 2014-12-20 Impact factor: 6.982
Authors: Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling Journal: Alzheimers Dement Date: 2018-04 Impact factor: 21.566
Authors: Markus Waser; Thomas Benke; Peter Dal-Bianco; Heinrich Garn; Jochen A Mosbacher; Gerhard Ransmayr; Reinhold Schmidt; Stephan Seiler; Helge B D Sorensen; Poul J Jennum Journal: Brain Behav Date: 2018-12-27 Impact factor: 2.708